Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of Nutex Health, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] Financial Performance - Nutex Health, Inc. reported a revenue decrease of $105.9 million to $151.7 million for Q4 and fiscal year 2025, attributed to a one-time $55.0 million cumulative true-up of 18,950 arbitration claims deemed ineligible under the IDR process [1] - Following the announcement of these financial results, Nutex's stock price fell by $15.06 per share, or 14.3%, closing at $90.28 per share on March 6, 2026 [1] Legal Investigation - The investigation by Pomerantz LLP focuses on whether Nutex and certain officers/directors engaged in securities fraud or other unlawful business practices [1] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [1]

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Nutex Health, Inc. (“Nutex” or the “Company”) (Nasdaq: NUTX) for potential violations of the federal securities laws. Shares of Nutex Health fell more than 24% in pre-market trading on March 6, 2026, after the company reported its fourth quarter and full-year 2025 results. Nutex disclosed that many out-of-network reimbursement claims it submitted throug ...

Core Insights - Nutex Health, Inc. announced a revenue decrease of $105.9 million to $151.7 million for Q4 and fiscal year 2025, attributed to a one-time $55.0 million cumulative true-up of arbitration claims deemed ineligible [1] Group 1: Financial Performance - The revenue for the three months ended December 31, 2025, was significantly impacted by arbitration claims [1] - The stock price of Nutex Health dropped following the announcement of these financial results [1] Group 2: Legal Investigation - Holzer & Holzer, LLC is investigating whether Nutex Health complied with federal securities laws in light of the recent financial disclosures [1]

Financial Data and Key Metrics Changes - Total revenue for 2025 reached $875.3 million, an 82% increase from $479.9 million in 2024 [5][22] - Net income increased to $70.8 million compared to $52.1 million in 2024 [5][28] - Adjusted EBITDA rose to $259.6 million, up 152.6% from $102.8 million in 2024 [6][29] - Cash on hand grew to $186 million as of December 31, 2025, up from $41 million a year earlier [8][42] Business Line Data and Key Metrics Changes - Hospital division revenue was $844.2 million in 2025, with mature hospitals increasing revenue by 73.4% [22][24] - Total patient visits increased to 188.3 thousand, an 11.8% rise from 168.4 thousand in 2024 [7][24] - Population health division revenue grew slightly by 0.7% to $31 million in 2025 [24] Market Data and Key Metrics Changes - The company reported a decrease in the current portion of long-term debt from $14.4 million to $13.3 million, while net long-term debt increased from $22.5 million to $29.2 million [8] - The ineligible claim submission rate for Nutex Health is approximately 8%, significantly better than the national average of 19% [10][38] Company Strategy and Development Direction - The company is focused on four priority areas: share repurchases, growth at existing hospitals, expansion of the Independent Physician Association (IPA), and real estate development strategy [15][18] - Nutex Health plans to open new hospitals in Jacksonville, West Little Rock, and San Antonio in 2026, with additional facilities planned for 2027 and 2028 [19][71] - The company aims to enhance its operational infrastructure to support higher throughput and a more diversified patient mix [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory challenges and optimize the Independent Dispute Resolution (IDR) process [20][63] - The company is optimistic about its growth trajectory entering 2026, supported by strong liquidity and operational improvements [20][42] Other Important Information - The company recognized a one-time $55 million revenue reduction related to arbitration claims deemed ineligible [9][30] - Total stock compensation expense for 2025 was $117 million, a significant increase from $16.6 million in 2024 [26] Q&A Session Summary Question: IDR-related submission rates and collection rates - The company noted a shift in IDR submission rates from 60%-70% to 50%-60%, with improved collection rates around 85% [56][60] - Management indicated that fewer submissions may reflect higher quality claims leading to better collections [62][65] Question: Reopening of a hospital in Texas - The decision to reopen was based on improved reimbursement through the IDR process and increased volume expectations [67][68] - Management confirmed they remain on track to open 5 to 6 facilities in 2026 and discussed a new real estate strategy to support this [71][72] Question: Timing of learning about the true-up adjustment - The company learned about the true-up adjustment in the middle of the fourth quarter, which was new information that required analysis before communication [77][79]

Nutex Health (NasdaqCM:NUTX) Q4 2025 Earnings call March 06, 2026 10:30 AM ET Company ParticipantsJennifer Rodriguez - Investor and Public Relations ManagerJon Bates - CFOTom Vo - Chairman and CEOWarren Hosseinion - PresidentWesley Bamburg - COOConference Call ParticipantsGene Mannheimer - Senior AnalystMichael Okunewitch - Senior Research AnalystOperatorGreetings. Welcome to Nutex Health's fourth quarter and full year 2025 10-K earnings call. At this time, all participants will be in listen-only mode. The ...

Nutex Health (NasdaqCM:NUTX) Q4 2025 Earnings call March 06, 2026 10:30 AM ET Speaker4Greetings. Welcome to Nutex Health's fourth quarter and full year 2025 10-K earnings call. At this time, all participants will be in listen-only mode. The question and answer session will follow the formal presentation. If anyone today should require operator assistance during the conference, please press star zero from your telephone keypad. Please note this conference is being recorded. At this time, I'll now turn the co ...

Core Insights - Nutex Health, Inc. shares fell over 24% in pre-market trading on March 6, 2026, following the release of Q4 and FY25 results, which revealed significant issues with out-of-network reimbursement claims [2] - The company reported a one-time cumulative true-up of $55.0 million related to 18,950 arbitration claims deemed ineligible under the Independent Dispute Resolution process [2] - Nutex acknowledged that previous results had been positively impacted by $69.0 million in arbitration revenues recorded in Q4 2024, stemming from submissions made in Q3 2024 [2] Investigation Details - Block & Leviton is investigating Nutex Health for potential securities law violations and may file actions to recover losses for affected investors [4] - Investors who purchased Nutex Health common stock and experienced a decline in share value may be eligible to participate in the investigation [3] Investor Actions - Affected investors are encouraged to contact Block & Leviton for more information on how to recover losses [5] - Whistleblowers with non-public information about Nutex Health are invited to assist in the investigation, with potential rewards for original information provided to the SEC [6]

Core Insights - Nutex Health reported significant financial growth for the fiscal year 2025, with total revenue reaching $875.3 million, an increase of 82.4% compared to $479.9 million in 2024 [1][2] - The company achieved an adjusted EBITDA of $259.6 million, reflecting a 152.6% increase from $102.8 million in 2024 [1][2] - Net income attributable to Nutex Health rose to $70.8 million in 2025, up from $52.1 million in 2024, marking an increase of $18.7 million [1][2] Financial Performance - Total assets as of December 31, 2025, were $918.5 million, with cash and cash equivalents of $185.6 million and long-term debt net of $29.2 million [1][2] - Operating income for 2025 was $275.6 million, compared to $130.7 million in 2024, representing a year-over-year improvement of $144.9 million [1][2] - The hospital division generated $844.2 million in revenue, a substantial increase of 188.0% from $449.1 million in 2024 [1][2] Operational Highlights - Total visits at the Hospital Division increased to 188,279 in 2025, up 11.8% from 168,388 in 2024 [1][2] - The company opened three new micro-hospitals in 2025, expanding its national footprint [2] - The company remediated all previously disclosed material weaknesses in internal controls over financial reporting in 2025, enhancing transparency and investor confidence [2] Stock Repurchase Program - The Board of Directors authorized a second stock repurchase program of up to $25.0 million to increase shareholder value and offset dilution from future stock compensation obligations [2][3] - The repurchase program allows the company to buy back shares in open market transactions or through privately negotiated transactions [2][3] Future Outlook - The company is well-positioned for continued growth through a balanced strategy that includes both new hospital development and increased patient volumes across existing facilities [2]

NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM FULL YEAR 2025 HIGHLIGHTS: HOUSTON, TX − (PRNewswire) – MARCH 5, 2026 – Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), today announced fourth quarter and fiscal year 2025 financial results for the twelve months ended December 31, 2025. Nutex Health is a physician-led, healthcare services and operations company with 27 hospital facilities in 12 states (hospital division), and a primary care-centric, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission file number 001-41346 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 11-3363609 (Stat ...